ALLR (Allarity Therapeutics) Accounts Receivable : $1.42 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Allarity Therapeutics's accounts receivables for the quarter that ended in Dec. 2024 was $1.42 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Allarity Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $1.34.

Allarity Therapeutics Accounts Receivable Historical Data

The historical data trend for Allarity Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics Accounts Receivable Chart

Allarity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

Get a 7-Day Free Trial

1.42

Allarity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Receivable	Get a 7-Day Free Trial														-	-	-	-	1.42

Allarity Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Allarity Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Allarity Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.416	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Allarity Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Allarity Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(19.533	+	0.75 * 1.416	+	0.5 * 0	-	10.839
-	0	-	0)	/	7.303
=	1.34

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Allarity Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Allarity Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 School Street, 2nd Floor, Boston, MA, USA, 02108

Website

https://www.allarity.com

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Executives

Laura Benjamin	director	168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano	director	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin	director	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown	officer: Chief Financial Officer	C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi	director, officer: Chief Executive Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen	officer: Chief Scientific Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen	officer: Chief Financial Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen	director	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore	director	C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen	officer: SVP, Information Technology	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem	officer: SVP, Chief Business Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh	officer: Chief Medical Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps	10 percent owner	VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass	10 percent owner	JERNBAEK ALLE 5, HELSINGE G7 DK-3200